Redhill Biopharma (NASDAQ: RDHL) — Company Overview, News & Financial Data
Redhill Biopharma develops drugs for gastrointestinal and cancer treatment, focused on addressing unmet medical needs with innovative therapies.
Redhill Biopharma
Redhill Biopharma (TASE:RDHL), (NASDAQ:RDHL) is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of a variety of diseases, including gastrointestinal and inflammatory disorders and cancer. With a deep commitment to innovation, Redhill conducts research and clinical development programs to bring new therapies to market that aim to improve patient outcomes. The company's portfolio spans both early and late-stage projects, targeting unmet medical needs with the potential to offer better efficacy or safety profiles than existing treatments. Redhill's objectives are centered on advancing its pipeline through clinical trials, securing partnerships for broader global reach, and ultimately transforming promising scientific discoveries into accessible medical solutions for patients worldwide.
Snapshot
Operations
Products and/or services of Redhill Biopharma
- Talicia - a treatment for Helicobacter pylori infection designed to reduce antibiotic resistance.
- Movantik - an oral solution for opioid-induced constipation in adult patients with chronic non-cancer pain.
- Opaganib - an orally-administered, sphingosine kinase-2 inhibitor being tested for multiple indications including COVID-19 and cancer.
- RHB-204 - an oral antibiotic combination therapy for the treatment of nontuberculous mycobacterial (NTM) infections.
- RHB-107 - an oral serine protease inhibitor targeting cancer, inflammatory disease, and COVID-19-related symptoms in outpatient settings.
- RHB-104 - a combination antibiotic therapy aimed at treating Crohn's disease with a suspected mycobacterial infection etiology.
Redhill Biopharma executive team
- Dror Ben-AsherCo-Founder, Chairman & CEO
- Razi IngberChief Financial Officer
- Gilead RadayChief Operating Officer
- Adi FrishChief Corporate & Business Development Officer
- Rick D. ScruggsChief Commercial Officer & Director
- Mark L. LevittChief Scientific Officer
- Alexandra OkmianSenior Business Development & Investor Relations Manager
- Reza FathiSenior Vice President of Research & Development
- Guy GoldbergChief Business Officer
- Patricia AndersonSenior Vice President of Regulatory Affairs
Latest news about Redhill Biopharma
RedHill acquires Rebyota and Clenpiq rights
United StatesRedHill's opaganib receives FDA rare pediatric disease designation for childhood cancer
United StatesRedHill Biopharma initiates enforcement of $10.9M judgment against Kukbo in Korea
United StatesRedHill Biopharma reports FY results, highlights strategic licensing and legal victories
United StatesRedHill targets $35B GLP-1 market loss with new side-effect therapy
United States
Key financials
Reported results for Redhill Biopharma, in USD.
- Market cap
- 3.7M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- 0.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 286K | -7.9M | -429K | |
| 8M | -14.6M | -8.3M | |
| 6.5M | 12.6M | 23.9M | |
| 61.8M | -42.8M | -71.7M |